Clinical Epigenetics · 2019 · 22 citations · 36 references
MedicineImmunologyMolecular BiologyEpigeneticsEpigenomicsMolecular OncologyCancer EpigeneticsCancer EpigenomicsDna Methylation ProfilingEpigenetic AlterationsEpigenetic Biomarker AnalysisEpigenetic BiomarkersCancer Epigenetic BiomarkersChronic Lymphocytic Leukemia TherapyDna Methylation PatternsEpigenetic Alterations In RecurrenceEpigenetic Chromatin StatesGenome-wide Methylation AnalysisPost-treatment RelapseRelapsed Chronic Lymphocytic Leukemia
BACKGROUND: In order to gain insight into the contribution of DNA methylation to disease progression of chronic lymphocytic leukemia (CLL), using 450K Illumina arrays, we determined the DNA methylation profiles in paired pre-treatment/relapse samples from 34 CLL patients treated with chemoimmunotherapy, mostly (n = 31) with the fludarabine-cyclophosphamide-rituximab (FCR) regimen. RESULTS: The extent of identified changes in CLL cells versus memory B cells from healthy donors was termed "epigenetic burden" (EB) whereas the number of changes between the pre-treatment versus the relapse sample was termed "relapse changes" (RC). Significant (p < 0.05) associations were identified between (i) high EB and short time-to-first-treatment (TTFT); and, (ii) few RCs and short time-to-relapse. Both the EB and the RC clustered in specific genomic regions and chromatin states, including regulatory regions containing binding sites of transcription factors implicated in B cell and CLL biology. CONCLUSIONS: Overall, we show that DNA methylation in CLL follows different dynamics in response to chemoimmunotherapy. These epigenetic alterations were linked with specific clinical and biological features.
36
DNA methylation age of human tissues and cell types
Steve Horvath · Genome biology · 2013 · 7.3K citations · Full text
Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia
Dan A. Landau, Scott L. Carter, Petar Stojanov et al. · Cell · 2013 · 1.4K citations · Full text